Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | BBI-940 |
| Synonyms | |
| Therapy Description |
Limited information is currently available on BBI-940, a putative kinesin degrader (Mar 2026). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| BBI-940 | BBI940|BBI 940 | Limited information is currently available on BBI-940, a putative kinesin degrader (Mar 2026). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07408089 | Phase I | BBI-940 + Fulvestrant BBI-940 | Study of the Kinesin Oral Molecular Degrader BBI-940 in Subjects With Advanced or Metastatic Breast Cancer (KOMODO-1) | Recruiting | USA | 0 |